
Fluidigm Corporation FLDM
Fluidigm Corporation Deferred Revenue 2011-2026 | FLDM
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Fluidigm Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 13.5 M | 11.8 M | 11.5 M | 10.2 M | 9.16 M | 9.42 M | 6.93 M | 2.72 M | 1.89 M | 2.01 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.5 M | 1.89 M | 7.91 M |
Deferred Revenue of other stocks in the Diagnostics research industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.34 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
441 M | $ 116.23 | 0.6 % | $ 35.3 B | ||
|
Akumin
AKU
|
7.53 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
547 K | - | -61.36 % | $ 2.46 M | ||
|
Co-Diagnostics
CODX
|
14.8 K | $ 1.67 | - | $ 2.22 M | ||
|
Aspira Women's Health
AWH
|
489 K | - | -6.19 % | $ 10.5 M | ||
|
Castle Biosciences
CSTL
|
6.62 M | $ 25.26 | 3.27 % | $ 702 M | ||
|
Chembio Diagnostics
CEMI
|
1.61 M | - | 0.22 % | $ 16.8 M | ||
|
CareDx, Inc
CDNA
|
4.65 M | $ 21.52 | 1.37 % | $ 1.15 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
19 K | - | - | $ 562 M | ||
|
DermTech
DMTK
|
196 K | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
2.68 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
4.14 M | - | - | $ 19.8 B | ||
|
Illumina
ILMN
|
260 M | $ 127.89 | 0.01 % | $ 20.3 B | ||
|
Fulgent Genetics
FLGT
|
2.23 M | $ 16.19 | -0.74 % | $ 490 M | ||
|
Global Cord Blood Corporation
CO
|
458 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
77.3 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
8.42 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
210 M | $ 172.96 | 1.88 % | $ 8.57 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
733 M | - | - | $ 10.7 B | ||
|
Guardant Health
GH
|
50.8 M | $ 90.69 | 2.0 % | $ 11.4 B | ||
|
Lantheus Holdings
LNTH
|
132 K | $ 84.36 | 0.04 % | $ 5.69 B | ||
|
Medpace Holdings
MEDP
|
854 M | $ 416.53 | 1.46 % | $ 12 B | ||
|
HTG Molecular Diagnostics
HTGM
|
185 K | - | -20.0 % | $ 1.06 M | ||
|
Heska Corporation
HSKA
|
5.08 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
54 K | $ 2.0 | 1.27 % | $ 8.85 M | ||
|
Koninklijke Philips N.V.
PHG
|
1.24 B | $ 27.72 | 0.91 % | $ 20 B | ||
|
Senseonics Holdings
SENS
|
628 K | $ 7.07 | 0.21 % | $ 295 M | ||
|
QIAGEN N.V.
QGEN
|
57.1 M | - | - | $ 10.6 B | ||
|
Neogen Corporation
NEOG
|
5.56 M | $ 9.6 | 0.58 % | $ 2.08 B | ||
|
National Research Corporation
NRC
|
16.2 M | $ 17.26 | 0.17 % | $ 386 M | ||
|
ICON Public Limited Company
ICLR
|
1.61 B | $ 102.05 | -0.12 % | $ 8.42 B | ||
|
Laboratory Corporation of America Holdings
LH
|
439 M | $ 265.38 | 0.62 % | $ 22.1 B | ||
|
Thermo Fisher Scientific
TMO
|
2.71 B | $ 470.88 | 0.28 % | $ 178 B | ||
|
Trinity Biotech plc
TRIB
|
4.44 M | $ 0.65 | 0.03 % | $ 61.9 M | ||
|
OpGen
OPGN
|
25.9 K | - | -16.95 % | $ 1.54 M | ||
|
NeoGenomics
NEO
|
851 K | $ 8.43 | 1.69 % | $ 1.08 B | ||
|
Twist Bioscience Corporation
TWST
|
6.88 M | $ 60.75 | -0.31 % | $ 3.63 B | ||
|
Myriad Genetics
MYGN
|
32.7 M | $ 4.79 | 0.1 % | $ 444 M | ||
|
Natera
NTRA
|
10.8 M | $ 206.25 | 1.23 % | $ 20.3 B | ||
|
Invitae Corporation
NVTA
|
4.81 M | - | - | $ 21.2 M | ||
|
PerkinElmer
PKI
|
160 M | - | -0.91 % | $ 14.7 B |